Like many other industries, clinical laboratories are becoming more reliant on data analytics. Clinical laboratories generate, process, and store transactional data with high quality and efficiency. These data are required for patient care and quality assurance activities and increasingly are used for operational decisions. To analyze all these data, laboratories often rely on commercial spreadsheets or other specialized software applications. However, these programs can be functionally limited and often are not suitable for more complex statistical analyses and visualizations or for analysis of large or high-dimensional datasets. Importantly, the analysis and visualization workflows in these programs have limited reproducibility and transparency.
Share
Northwestern University professors Sossina Haile and Dr. Dimitri Krainc have received the 16th annual Dorothy Ann and Clarence L. Ver Steeg Distinguished Research Fellowship Award.
Haile, of the McCormick School of Engineering, is a fuel cell pioneer whose work focuses on sustainability and social good on a global scale. Krainc, of Northwestern University Feinberg School of Medicine, is an outstanding investigator in the field of neurodegenerative research whose work has paved the way for investigations into novel therapeutics.
Bestowed by the Office of the Provost, the Ver Steeg Fellowship supports scholarship and research by tenured Northwestern faculty whose work enhances the national and international reputation of the University. The honor includes a $40,000 award for each recipient.
Share this article
Share this article
SAN DIEGO, Calif. and CALGARY, AB, May 20, 2021 /PRNewswire/ Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced clinical and biomarker data demonstrating clinical proof-of-concept for pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer. The data will be featured in an upcoming electronic poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place virtually from June 4 – 8, 2021.
The newly announced data are from a phase 2 trial evaluating pelareorep in combination with the PD-1 inhibitor pembrolizumab (KEYTRUDA®) in pancreatic adenocarcinoma patients who progressed after first-line treatment. Findings from the trial indicate that pelareorep and pembrolizumab synergize and show anti-cancer activity in these difficult-to-treat patients, which is mediated through the complementary immunotherapeutic effects of the two agents.